Search

Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10 Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020 QR-1123 Investigational New Drug application active for autosomal dominant re

LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct.

LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct.

Des améliorations rapides, significatives et durables de la vision à douze mois ont été rapportéesAmélioration concordante des mesures des résultats secondaires clésLa dose d'enregistrement cible du sepofarsen a été bien tolérée avec un profil risque/bénéfice fa

Reported rapid, significant and durable improvements in vision at twelve months Concordant improvement in key secondary outcome measures The target registration dose of sepofarsen was well-tolerated with a favorable benefit/risk profile Strengthens confidence

LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct.

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept.

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept.